Friday, July 14, 2017

FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33%

Today's Daily Dose brings you news about Alder's stock offering; FDA panel recommendation of 2 biosimilar candidates; Sangamo's investigational drugs SB-318 and SB-913 getting Fast Track designation; Pfizer's upcoming regulatory catalyst related to its rheumatoid arthritis drug; Mallinckrodt's progress in its CONFIRM trial and MiMedx Group's better-than-expected Q2 revenue.

from RTT - Biotech http://ift.tt/2upiUrL
via IFTTT

No comments:

Post a Comment